Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blinded, Placebo-controlled Study of (ERC1671/GM-CSF/Cyclophosphamide)+Bevacizumab vs. (Placebo Injection/Placebo Pill) +Bevacizumab in the Treatment of Recurrent/Progressive, Bevacizumab naïve Glioblastoma Multiforme and Glioasarcoma Patients (WHO Grade IV Malignant Gliomas, GBM)

Next Previous
X
Search
Trial Profile

A Randomized, Double-blinded, Placebo-controlled Study of (ERC1671/GM-CSF/Cyclophosphamide)+Bevacizumab vs. (Placebo Injection/Placebo Pill) +Bevacizumab in the Treatment of Recurrent/Progressive, Bevacizumab naïve Glioblastoma Multiforme and Glioasarcoma Patients (WHO Grade IV Malignant Gliomas, GBM)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ERC 1671 (Primary) ; Bevacizumab; Cyclophosphamide; Sargramostim
  • Indications Glioblastoma; Gliosarcoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Epitopoietic Research Corporation

    • Most Recent Events

    • 20 Jul 2021 Status changed from recruiting to active, no longer recruiting.
    • 07 Apr 2021 According to a University of California media release, the FDA has recommended early termination of this trial in a letter dated April 2, 2021 and recommended to pursue a randomized confirmatory Phase 3 registration trial to support a licensing application in the form of a biologics license application (BLA).
    • 19 Aug 2020 According to an Epitopoietic Research Corporation media release, this trial is under FDA IND 15430 at the University of California, Irvine Medical Center in Orange, California.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top